TRAW vs. NERV, COCP, TNXP, VAXX, NNVC, AYTU, TLPH, VBIV, INDP, and NRSN
Should you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Minerva Neurosciences (NERV), Cocrystal Pharma (COCP), Tonix Pharmaceuticals (TNXP), Vaxxinity (VAXX), NanoViricides (NNVC), Aytu BioPharma (AYTU), Talphera (TLPH), VBI Vaccines (VBIV), Indaptus Therapeutics (INDP), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical preparations" industry.
Traws Pharma (NASDAQ:TRAW) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.
In the previous week, Minerva Neurosciences had 1 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for Minerva Neurosciences and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.44 beat Minerva Neurosciences' score of 0.96 indicating that Traws Pharma is being referred to more favorably in the media.
Minerva Neurosciences received 347 more outperform votes than Traws Pharma when rated by MarketBeat users.
Traws Pharma has higher revenue and earnings than Minerva Neurosciences. Traws Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Traws Pharma has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.
8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 3.3% of Traws Pharma shares are held by insiders. Comparatively, 6.4% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Minerva Neurosciences has a net margin of 0.00% compared to Traws Pharma's net margin of -8,384.07%. Minerva Neurosciences' return on equity of 0.00% beat Traws Pharma's return on equity.
Minerva Neurosciences has a consensus price target of $7.00, indicating a potential upside of 172.51%. Given Minerva Neurosciences' higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Traws Pharma.
Summary
Minerva Neurosciences beats Traws Pharma on 9 of the 14 factors compared between the two stocks.
Get Traws Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Traws Pharma Competitors List
Related Companies and Tools
